Modernization and Expansion of the University of Illinois at Chicago Animal-Based Research Program

摘要 伊利诺伊大学芝加哥分校（UIC）在健康差异研究方面开发了高度认可的项目 并且是城市公共机构中的全国领导者，通过以下方式为不同的患者群体提供护理： 医院和社区临床系统。我们的UIC研究计划围绕我们的 不同的人群和社区，重点是了解疾病机制，开发新的 治疗和完善与我们的患者基础相关的临床方法。我们的临床前建模 能力和实验室动物研究设施现在需要扩大，以连接我们的研究机会， 生成和表征人类疾病模型的能力，以支持我们的核心使命领域。UIC 建议通过对动物研究项目进行关键性的革新， 生物资源实验室（BRL），该机构的集中动物设施。该项目将包括 翻修和升级供暖、通风和空调系统的基本要素， BRL的电气系统，以增加住房容量，并适应该机构的鼠- 癌症和代谢研究项目。这些包括患者来源的类器官和异种移植物 模型核心使用来自代表性不足的癌症患者人群的样本和一个新的代谢 疾病核心模型在治疗心血管和代谢疾病的健康差距。等 现代化还将大大提高能源效率。总体而言，UIC BRL的改进将支持 动物为基础的研究，并允许我们的健康转化和临床研究计划的扩展 差异和药物发现。UIC BRL扩展的长期影响将维持我们的计划， 在健康差异研究和药物发现方面的卓越转化，同时允许我们的NIH的增长， 受资助的基于人口的研究项目（我们所有人都在伊利诺伊州精准医学联盟，UIC 少数民族健康研究所和我们的CTSA支持的临床和转化科学中心） 和我们的UI癌症中心这一扩张也将影响我们的区域合作伙伴的研究计划， 依靠我们在动物研究方面的设施、核心和能力。最后，我们的基于战略的 计划和营利性合作伙伴关系，以推动药物发现计划，也迫使我们的扩大， 基于动物的临床前建模能力。

Abstract The University of Illinois at Chicago (UIC) has developed highly recognized programs in health disparity research and is a national leader among urban, public institutions that provide care for diverse patient populations through its hospital and community-based clinical systems. Our UIC research programs have developed around our diverse populations and communities with a focus on understanding disease mechanisms, developing novel therapeutics and refining clinical approaches that have relevance to our patient base. Our preclinical modeling capability and laboratory animal research facilities now require expansion to link our research opportunities with the capability to generate and characterize models of human disease that support our core mission areas. UIC proposes to modernize and expand its animal-based research programs by performing critical renovations to the Biologic Resources Laboratory (BRL), the institution’s centralized animal facility. The project will comprise renovations and upgrades to essential elements of the heating ventilation and air conditioning (HVAC) and electrical systems in the BRL to increase housing capacity and accommodate growth in the institution’s murine- based cancer and metabolic research programs. These include a patient-derived organoid and xenograft modeling core that uses samples from underrepresented cancer patient populations and a new Metabolic Disease Core to model health disparities in the treatment of cardiovascular and metabolic diseases. Such modernization will also result in significant energy efficiencies. Overall, UIC BRL improvements will support animal-based research and permit the expansion of our translational and clinical research programs in health disparities and drug discovery. The long-term impact of the UIC BRL expansion will sustain our programs of translational excellence in health disparities research and drug discovery while permitting the growth of our NIH- funded population-based research programs (All of Us within the Illinois Precision Medicine Consortium, UIC Institute for Minority Health Research, and our CTSA-supported Center for Clinical and Translational Sciences) and our UI Cancer Center. This expansion will also impact the research programs of our regional partners who rely upon our facilities, cores and capability in animal research. Finally, our entrepreneurship-based strategic plan and for-profit partnerships to drive drug discovery initiatives have also compelled the expansion of our animal-based preclinical modeling capabilities.